Patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 500 nM of mivebresib, 500 nM of dual PI3K/mTOR inhibitor dactolisib or 1000 nM of IAP antagonist LCL-161 for 24 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with these small molecules in MECOM-rearranged AML cells with EVI1 overexpression.